Allergen plc company logo

# 1st Gen Model Allergen plc Pharmaceutical preparations

Subscribe >> Deal exit on
Oct. 23, 2017
Deal entry on
Oct. 23, 2017
3.92%Expected margin
57.29% successful of 96 deals
$188.28 Last close price
at 20-oct-2017
  • Top 20 Accuracy

AGN

Model's trade recommendations -14.19% Return for period

-13.09% Annual return

$62.57B Market Cap

β 1.15  

AGN

Model (following trade recommendations)

AGN

Underlying stock

S&P 500

Index
Return for period -14.19%
-11.02%
1.78%
52wk return -30.48%
-18.31%
16.82%
52wk Range
187.15—256.15
2000.54—2399.63
Sortino ratio -1.05
Sharpe ratio -0.89
Norm. RMSE 0.86%
Downside risk 12.55%
Volatility 14.92%
  • 2.80 (1.50%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Allergen plc (AGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for AGN model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 333M
P/E 12.83
Shares Outstanding 334M
% Held by Insiders 0.36%
% Held by Institutions 81.94%
EPS (last reported FY) $13.51
EPS (last reported Q) $4.02
EPS, estimated (last reported Q) $3.95
Total revenues $15 B
Net income $15 B